PrEPferences:

Closing the PrEP gap to end the HIV epidemic

Introduction
Ensuring diverse PrEP options is essential to improving medication adherence among patients at risk for HIV. By aligning therapy choices with individual lifestyles, preferences, and tolerability, we empower patients to remain consistent in prevention. This presentation explores how tailored PrEP strategies support adherence and long-term success in HIV prevention efforts.

Purpose
The purpose of this project is to evaluate how competent patients’ preferences for PrEP options evolve over time. By understanding shifts in choice, motivation, and adherence behavior, we aim to inform patient-centered care strategies that support long-term HIV prevention and improve outcomes through responsive, adaptable treatment planning.

Annual PrEP Implant

(Nexplanon technology, Implant)

Once-annual subdermal implant.

Merck

Not FDA approved.

Investigational.

33.9%

Yeztugo

(lenacapavir, injection)
6-month subcutaneous injectable.
Gilead Sciences, Inc. 2025,

FDA Approved

33.9%

Apretude

(cabotegravir, injection)
2-month intramuscular injectable.
ViiV Healthcare, GlaxoSmithKline Pharmaceuticals
2021, FDA Approved

7.4%

MK-8591

(Islatravir, tablet)
Once-monthly oral tablet.
Merck
Not FDA Approved. Investigational.

26.4%

Descovy

(emtricitabine & tenofovir alafenamide)
Once-daily oral tablet.
Gilead Sciences, Inc.
2018, FDA Approved

10.9%

Sample Size: 201

Data Analysis

In our data analysis, we observed a clear shift in patient preferences toward longer-acting PrEP treatments, reflecting a desire for convenience and reduced dosing frequency. However, the data also reveals a consistent underlying priority: patients value minimally invasive options. This highlights the importance of balancing efficacy with comfort and accessibility.

Outcomes
The purpose of this project is to evaluate how competent patients’ preferences for PrEP options evolve over time. By understanding shifts in choice, motivation, and adherence behavior, we aim to inform patient-centered care strategies that support long-term HIV prevention and improve outcomes through responsive, adaptable treatment planning.

Conclusion
In conclusion, our findings underscore the critical importance of offering diverse, patient-centered PrEP options to support evolving preferences and improve adherence. While long-acting treatments are increasingly favored, patients consistently value minimally invasive approaches. Providing flexible, accessible PrEP strategies fosters greater engagement, satisfaction, and sustained HIV prevention, reinforcing the need for individualized care models.

Authors
University of Central Florida, College of Medicine: Dr. Humberto Castillo Lopez, MD
University of Central Florida, College of Nursing: Christopher W. Blackwell, Ph.D., APRN, ANP-BC, AGACNP-BC, CNE, FAANP, FAAN

Pineapple Healthcare:
Erick Suarez, APRN, FNP-BC, AAHIV-S; Christian Otero, PA-C, AAHIV-S; Derek Glenn Eiflander, APRN, FNP-C, AAHIV-M; Emma Victoria Ayson, APRN, FNP-C, AAHIV-S; Eliza Otero, APRN, FNP-C, AAHIV-S; Eric Lee Johnson, RN, BSN; Haide Medina Rodriguez, RN, BSN; Michelle Suarez Ochoa, LPN

References

Centers for Disease Control and Prevention. (2023). HIV and gay and bisexual men. U.S.
Department of Health & Human Services. https://www.cdc.gov/hiv/data-research/facts-
stats/gay-bisexual-men.html

Contagion Live. (2025, January 17). Undermining HIV prevention now will cost billions later.
https://www.contagionlive.com/view/undermining-hiv-prevention-now-will-cost-billions-
later

Infectious Diseases Society of America. (2024, July 25). AIDS 2024: Studies show strong user
preference for long-acting injectable PrEP. IDSA Science Speaks Blog.
https://www.idsociety.org/science-speaks-blog/2024/aids-2024-studies-show-strong-user-
preference-for-long-acting-injectable-prep/

Pfau, B., et al. (2025). User preferences on longacting preexposure prophylaxis for HIV
prevention in East and Southern Africa: a systematic review. BMC Public Health.
New York State Department of Health AIDS Institute. (2025, February). Pre-exposure
prophylaxis (PrEP) for HIV prevention: Lenacapavir (LEN) guidance. HIV Clinical
Guidelines Program. https://www.hivguidelines.org/guideline/hiv-prep-len/

Lorenzetti, L., Dinh, N., van der Straten, A., Fonner, V., Ridgeway, K., Rodolph, M., Schaefer,
R., Schmidt, H. A., & Baggaley, R. (2023). Systematic review of the values and
preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV
acquisition. Journal of the International AIDS Society, 26 Suppl 2(Suppl 2), e26107.
https://doi.org/10.1002/jia2.26107

Ogunbajo A, Euceda A, Ekundayo R, Smith J, Oke T, et al. (2025) Preferences for on-
demand/intermittent/event-driven and long-acting injectable (LAI) HIV pre-exposure
prophylaxis (PrEP) among HIV-negative Black gay, bisexual, and other sexual minority

men in the United States: A qualitative study. PLOS ONE 20(6):
e0323212. https://doi.org/10.1371/journal.pone.0323212

Martin, C. E., Rousseau-Jemwa, E., Adeagbo, O., Mweli, N., Zule, W., Govender, K., Etima, J.,
Khubone, T., Mullick, S., & Scorgie, F. (2025). Real-world experiences of oral PrEP
access and use for adolescent girls and young women in South Africa: A qualitative
study. AIDS and Behavior. https://doi.org/10.1007/s10461-024-04596-5

Pineapple Healthcare. (n.d.). Pineapple Healthcare. https://www.pineapplehealthcare.com
Rogers, E. M. (2003). Diffusion of innovations (5th ed.). Free Press.

Schuyler, A., Alidina, Z., Dolcini, M. M., Harper, G., Fortenberry, J. D., Singh, R., Jamil, O.,
Pollack, L., & Catania, J. (2021). Pre-Exposure Prophylaxis (PrEP) dissemination:
Adapting diffusion theory to examine PrEP adoption. AIDS and Behavior, 25(10),
3145–3158. https://doi.org/10.1007/s10461-021-03345-2

The American Journal of Managed Care. (2024, March 18). Overcoming barriers to HIV
prevention: Population health considerations on optimizing PrEP access. AJMC.
https://www.ajmc.com/view/overcoming-barriers-to-hiv-prevention-population-health-
considerations-on-optimizing-prep-access

Wang, H., de Wit, J., & Adam, P. (2024). Intention and preference to use long-acting injectable
PrEP among MSM in the Netherlands: Applying a diffusion of innovation approach.
AIDS Care, 36(4), 476–484. https://doi.org/10.1080/09540121.2024.2307378